SGIOY News and Press, Shionogi & Co. Ltd. ADR From 05/19/20

Genocea Biosciences (NASDAQ: GNCA ) inks a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. ( OTCPK:SGIOY ) to develop a novel herpes simplex virus type 2 (HSV-2) vaccine. More news on: Genocea Biosciences, Inc., Shionogi & Co., Ltd., Healt...

ViiV Healthcare announces positive preliminary results from the HIV Prevention Trials Network 083 study evaluating cabotegravir for the prevention of HIV infection. More news on: GlaxoSmithKline plc, Pfizer Inc., Shionogi & Co., Ltd., Healthcare stocks news, Read more ...

Health Canada has approved ViiV Healthcare's Cabenuva (cabotegravir and rilpivirine extended-release injectable suspensions), a once-monthly regimen for HIV-1-infected adults who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). More news on: GlaxoSmithKline plc...

ViiV Healthcare has renewed its research agreement , aimed at finding a cure for HIV infection, with the University of North Carolina - Chapel Hill to the tune of $20M over five years. The parties have been working together since 2015. More news on: GlaxoSmithKline plc, Pfizer Inc., Shion...

Results from a Phase 3 clinical trial, ATLAS-2M , evaluating the combination of ViiV Healthcare's cabotegravir and Johnson & Johnson's ( JNJ -2.7% ) rilpivirine for the treatment of HIV infection showed the non-inferiority (no worse than) of a two-month dosing interval compared to ...

ViiV Healthcare has submitted a marketing application in Europe for fostemsavir, combined with other antiretrovirals, for the treatment of adults with multidrug-resistant HIV-1 infection. More news on: GlaxoSmithKline plc, Pfizer Inc., Shionogi & Co., Ltd., Healthcare stocks news, ...

ViiV Healthcare has filed marketing applications in the U.S. and Europe for a 5 mg dispersible tablet formulation of dolutegravir for HIV-positive children as well as a simplified dosing regimen aimed at optimizing the use of the existing dolutegravir 50 mg film-coated tablet for pediatric...

ViiV Healthcare has submitted a supplemental marketing application to the FDA seeking approval to use Dovato (dolutegravir and lamivudine) as a switch treatment for HIV-1 infection in virologically suppressed adults on a stable antiretroviral regimen with no treatment failure. More news ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...